BIOD351
Specialty Medication
Final Test Exam Review (Qns & Ans)
2025
1. Which of the following specialty medications is used to treat
multiple sclerosis by modulating the immune response?
- A. Infliximab
- B. Glatiramer acetate
- C. Rituximab
- D. Adalimumab
ANS: B. Glatiramer acetate
©/2025
, Rationale: Glatiramer acetate is an immunomodulator used to
treat multiple sclerosis by modifying the immune response and
reducing the frequency of relapses.
2. What is the primary mechanism of action of biologic
DMARDs (disease-modifying antirheumatic drugs) like
etanercept in treating rheumatoid arthritis?
- A. Inhibiting T-cell activation
- B. Blocking tumor necrosis factor (TNF)
- C. Inhibiting DNA synthesis
- D. Stimulating B-cell proliferation
ANS: B. Blocking tumor necrosis factor (TNF)
Rationale: Biologic DMARDs like etanercept work by
blocking the activity of TNF, a pro-inflammatory cytokine,
thereby reducing inflammation and preventing joint damage in
rheumatoid arthritis.
Fill-in-the-Blank Questions
3. __________ is a monoclonal antibody used to treat HER2-
positive breast cancer by targeting the HER2 receptor on cancer
cells.
©/2025
, ANS: Trastuzumab
Rationale: Trastuzumab is a monoclonal antibody that targets
the HER2 receptor, inhibiting the growth of HER2-positive breast
cancer cells.
4. The medication __________ is an oral tyrosine kinase
inhibitor used to treat chronic myeloid leukemia (CML) by
inhibiting the BCR-ABL fusion protein.
ANS: Imatinib
Rationale: Imatinib is a tyrosine kinase inhibitor that
specifically targets the BCR-ABL fusion protein, which is
involved in the pathogenesis of CML.
True/False Questions
5. True or False: Monoclonal antibodies used in cancer therapy
are designed to specifically target cancer cells while minimizing
damage to normal cells.
ANS: True
Rationale: Monoclonal antibodies are designed to specifically
target cancer cells by recognizing and binding to specific
antigens, thereby minimizing damage to normal cells.
©/2025
, 6. True or False: Biosimilars are exact replicas of biologic
medications and do not require clinical testing before approval.
ANS: False
Rationale: Biosimilars are similar, but not identical, to
original biologic medications. They require clinical testing to
demonstrate that they are as safe and effective as the reference
product before approval.
Multiple Response Questions
7. Which of the following medications are classified as immune
checkpoint inhibitors used in cancer immunotherapy? (Select all
that apply)
- A. Pembrolizumab
- B. Nivolumab
- C. Methotrexate
- D. Bevacizumab
ANSs: A, B
Rationale: Pembrolizumab and Nivolumab are immune
checkpoint inhibitors used in cancer immunotherapy to enhance
©/2025
Specialty Medication
Final Test Exam Review (Qns & Ans)
2025
1. Which of the following specialty medications is used to treat
multiple sclerosis by modulating the immune response?
- A. Infliximab
- B. Glatiramer acetate
- C. Rituximab
- D. Adalimumab
ANS: B. Glatiramer acetate
©/2025
, Rationale: Glatiramer acetate is an immunomodulator used to
treat multiple sclerosis by modifying the immune response and
reducing the frequency of relapses.
2. What is the primary mechanism of action of biologic
DMARDs (disease-modifying antirheumatic drugs) like
etanercept in treating rheumatoid arthritis?
- A. Inhibiting T-cell activation
- B. Blocking tumor necrosis factor (TNF)
- C. Inhibiting DNA synthesis
- D. Stimulating B-cell proliferation
ANS: B. Blocking tumor necrosis factor (TNF)
Rationale: Biologic DMARDs like etanercept work by
blocking the activity of TNF, a pro-inflammatory cytokine,
thereby reducing inflammation and preventing joint damage in
rheumatoid arthritis.
Fill-in-the-Blank Questions
3. __________ is a monoclonal antibody used to treat HER2-
positive breast cancer by targeting the HER2 receptor on cancer
cells.
©/2025
, ANS: Trastuzumab
Rationale: Trastuzumab is a monoclonal antibody that targets
the HER2 receptor, inhibiting the growth of HER2-positive breast
cancer cells.
4. The medication __________ is an oral tyrosine kinase
inhibitor used to treat chronic myeloid leukemia (CML) by
inhibiting the BCR-ABL fusion protein.
ANS: Imatinib
Rationale: Imatinib is a tyrosine kinase inhibitor that
specifically targets the BCR-ABL fusion protein, which is
involved in the pathogenesis of CML.
True/False Questions
5. True or False: Monoclonal antibodies used in cancer therapy
are designed to specifically target cancer cells while minimizing
damage to normal cells.
ANS: True
Rationale: Monoclonal antibodies are designed to specifically
target cancer cells by recognizing and binding to specific
antigens, thereby minimizing damage to normal cells.
©/2025
, 6. True or False: Biosimilars are exact replicas of biologic
medications and do not require clinical testing before approval.
ANS: False
Rationale: Biosimilars are similar, but not identical, to
original biologic medications. They require clinical testing to
demonstrate that they are as safe and effective as the reference
product before approval.
Multiple Response Questions
7. Which of the following medications are classified as immune
checkpoint inhibitors used in cancer immunotherapy? (Select all
that apply)
- A. Pembrolizumab
- B. Nivolumab
- C. Methotrexate
- D. Bevacizumab
ANSs: A, B
Rationale: Pembrolizumab and Nivolumab are immune
checkpoint inhibitors used in cancer immunotherapy to enhance
©/2025
